a-Synuclein is the 140 amino acid presynaptic protein 1, 2 that forms Lewy bodies and other lesions in a spectrum of brain disorders referred to as synucleinopathies, which include Parkinson's disease, the second most common neurodegenerative disorder, as well as dementia with Lewy bodies, Lewy body variant of Alzheimer's disease, multiple system atrophy, and neurodegeneration with brain iron accumulation type I. 3, 4 A causative role for a-synuclein in neurodegeneration is established by the presence of missense mutations and multiplication of the a-synuclein gene in rare families with autosomal dominant Parkinson's disease. [3] [4] [5] [6] Thus, factors that regulate production and steady-state levels of a-synuclein are potentially relevant to pathogenesis.
Brain iron homeostasis is known to be disrupted in Parkinson's disease and other synucleinopathies such as neurodegeneration with brain iron accumulation type I, 7 but the link between iron and a-synuclein pathology has remained unclear. Iron homeostasis is achieved in part by post-transcriptional regulation through highly conserved messenger RNA (mRNA) stem loops called iron regulatory elements (IREs), which are present in the untranslated regions (UTRs) of a number of transcripts essential to iron metabolism. 7, 8 Here we provide the first report of a putative IRE in the 5 0 -UTR of mRNA encoding the 140-residue a-synuclein and predict that this RNA structure posttranscriptionally regulates a-synuclein protein production in response to cellular iron and redox events.
We used computer-generated folding to assess the secondary structure of the transcript encoding the 140 amino acid a-synuclein. The 46 nucleotide 5 0 -UTR is computer predicted to form a single RNA stem loop (Gibbs free energy = À53 kcal/mol), 9 redrawn in Figure 1a . The stem loop shows striking similarity to the H-ferritin IRE (Figure 1a) , and to similar IREs in the 5 0 -UTRs of mRNAs encoding L-ferritin, ferroportin, and erythroid 5-aminolevulinate (eALAS) and mitochondrial aconitase, including 100% homology at the five nucleotide apex. Alignment of the canonical a-synuclein mRNA 5 0 -CAGUG 0 -3 0 stem-loop motif against the 5 0 -CAGUG-3 0 sequence in mRNAs encoding ferritin H and L chains, ferroportin, and erythroid 5-aminolevulinate (eALAS) reveals core homology residues in the IREs, with homology most prominent in proximity to the canonical 5 0 -CAGUG-3 0 motif, particularly on the 5 0 aspect. a-synuclein is a member of a family of proteins that includes b-and g-synuclein, which are also highly expressed in brain. 4 Although b-and g-synuclein show a high degree of homology to a-synuclein at the protein level, they do not contain IRE-like sequences within their respective mRNAs 10 and do not prominently deposit with a-synuclein in brain lesions. 4 Similarly, alternatively spliced a-synuclein mRNAs, which lack the IRE-like sequence encode 112 and 126 amino acid proteins that do not appear to nucleate and fibrillize with the 140 amino acid species. 10 Highlighted in gray are the core homology residues among a-synuclein and the known iron responsive elements, with the homology most prominent in proximity to the canonical 5 0 -GAGUG-3 0 motif, particularly on the 5 0 aspect.
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Across mammalian species in the evolutionary ladder, a-synuclein protein is highly conserved, even though synucleinopathy develops selectively in humans. Only the human a-synuclein mRNA contains an IRE-like sequence in its 5 0 -UTR, and, of note, generation of the human a-synuclein transcript requires RNA splicing out of an intron that precisely interrupts the canonical 5 0 -CAGUG-3 0 motif of the predicted 5 0 UTR stem loop. 10 Thus, it is possible that a unique role for a-synuclein in presynaptic redox and iron metabolism rapidly evolved in primates with selection for RNA splicing that favored a gain of post-transcriptional regulation for a-synuclein protein production.
If the novel stem-loop structure we describe in asynuclein mRNA functions to confer iron dependent post-transcriptional control, it would have implications for the central nervous system amyloidoses. It would immediately suggest a mechanism for induction of asynuclein by an age-related iron or redox pathophysiology upstream of neurodegeneration. Furthermore, it would provide an explanation for the well-characterized neuropathologic association of a-synuclein and the Alzheimer b-amyloid protein 3 since the Alzheimer bamyloid precursor protein mRNA also contains an IRE in its 5 0 -UTR. 8 If and how the IRE-like structure in asynuclein mRNA functions as a post-transcriptional regulator now awaits experimental clarification. Cocaine-amphetamine-regulated transcript (CART) gene was identified in 1995 in a search for mRNAs in the striatum acutely upregulated by psychostimulants. 1 CART is highest expressed in the hypothalamus and widely expressed in the central and peripheral nervous systems, as well as in endocrine cells.
1,2 CART peptides have received much attention as mediators of stress, reward and reinforcement, appetite control, addiction and neuroendocrine regulation. 2 Recent studies link a mutation in the CART gene to obesity, type-II diabetes, anxiety and depression, and the mutation leads to CART deficiency or altered CART peptide levels, indicating a genetic cause for these human diseases or disorders. [3] [4] [5] [6] Although CART peptides have versatile functions, the mechanisms that mediate CART's effects are still poorly understood. Interestingly, intracerebroventricular injections of CART not only influenced food intake but also induced c-Fos expression in areas of the rat brain that are involved in feeding behavior. 7 Furthermore, CART knockout mice displayed increased body weight, and marked reduction of the expression of some important genes, such as pancreatic duodenal homeobox 1 (PDX-1) and glucose transporter-2 (GLUT-2) in pancreatic islets. 8 Thus, we tested the hypothesis that CART may have transcription function by a putative approach 9 in mammalian cells. First, we fused the conserved C-terminal region (residues 62-102) of CART 1 in-frame to the Gal4 DNA-binding domain (residues 1-147) of pM, a mammalian expression vector (BD Clontech, Palo Alto, CA, USA). The resulting plasmid pMCART was confirmed by DNA sequencing and the fusion protein was recognized by CART antibody (Phoenix, Inc., Belmont, CA, USA). We co-transfected pMCART or pM into HEK293 cells, a human embryonic kidney cell line, together with pTK-Gal-Luc, a Gal4-depending luciferase reporter vector that contains the firefly luciferase gene downstream of five consensus Gal4-binding sites and the minimal HSV-TK promoter, and with pcDNALacZ plasmid as an internal control for transfection efficiency. At 28 h after transfection, luciferase and b-galactosidase assays were performed on cell lysates using the commercial kits (Promega, Madison, WI, USA) according to the protocols. Luciferase activity of transgenes was normalized by b-galactosidase activity and is expressed as 'relative luciferase units' (RLU). The Gal4 domain alone (pM vector) caused a basic increase in luciferase activity;
